HepaTx, a biotechnology company focused on cell therapy for liver diseases, is thrilled to announce the appointment of Dr. Mack C. Mitchell to its Clinical Advisory Board. With his extensive gastroenterology and clinical pharmacology expertise, Dr. Mitchell brings invaluable knowledge to the team.
Dallas, TX - Palo Alto, CA – 7/10/2023 - HepaTx, a biotechnology company focused on cell therapy for liver diseases, is thrilled to announce the appointment of Dr. Mack C. Mitchell to its Clinical Advisory Board. With his extensive gastroenterology and clinical pharmacology expertise, Dr. Mitchell brings invaluable knowledge to the team.
Dr. Mitchell currently serves as Vice-President for Medical Affairs and the Nancy and Jeremy Halbreich Professor of Gastroenterology at U.T. Southwestern Medical Center in Dallas. He was previously Chief Medical Officer for Southwestern Health Resources, a renowned clinically integrated physician network, Vice-chair for Clinical Operations in the Department of Internal Medicine, and interim Executive Vice President for the Health System at U.T. Southwestern. Prior to his tenure at U.T. Southwestern, Dr. Mitchell held significant positions including Director of Gastroenterology at Johns Hopkins Bayview Medical Center in Baltimore, MD, and Chair of Medicine at Carolinas Medical Center in Charlotte, NC.
Dr. Mitchell’s career is marked by numerous achievements and recognition by professional organizations. He was elected to Phi Beta Kappa and Alpha Omega Alpha honorary societies and has attained fellowships in the American College of Physicians and the American Association for the Study of Liver Diseases. A trailblazer in alcohol-associated hepatitis research, Dr. Mitchell has made significant contributions to the field. He has served on the Advisory Council and as Chair of the Board of Scientific Councilors of the National Institute of Alcohol Abuse and Alcoholism. Additionally, Dr. Mitchell is President of the Alcoholic Beverage Medical Research Foundation. At U.T. Southwestern, he currently leads the research team as the principal investigator for AlcHepNet, an NIH-sponsored clinical research study on alcohol-associated hepatitis. Dr. Mitchell’s expertise has led him to co-author numerous research publications and chapters, including the influential American Gastroenterology Association guidelines on alcohol-associated hepatitis.
Eric Schuur, PhD, CEO of HepaTx said, “I’m very pleased with the addition of Dr Mitchell to our Clinical Advisory Board. His extensive experience and leadership in hepatology and especially in alcohol-related hepatitis will be a tremendous asset in our efforts to bring innovative care to this large and under-served group of patients.”
Dr. Mitchell commented, “I’m impressed with HepaTx and their research results to date. The company’s approach is innovative and, if proven in clinical studies, will significantly improve treatment for individuals suffering from alcohol-related hepatitis and potentially other liver diseases.”
Dr. Mitchell’s appointment to HepaTx’s Clinical Advisory Board is a testament to his exceptional expertise and accomplishments in the field of gastroenterology. His invaluable insights will significantly contribute to HepaTx’s progress toward developing innovative liver disease therapeutics, ultimately revolutionizing patient care.
About HepaTx
HepaTx is a cell therapy and regenerative medicine company developing cell-based treatments for late-stage liver disease, a highly underserved and cost-intensive market. To learn more, visit our website, Hepatx.com, and follow us on Twitter, @hepatx, and LinkedIn.
Contact:
HepaTx
Claudia Preziosi
cpreziosi@hepatx.com